Study Stopped
PhD Student completed primary study. Awaiting a new student to take over the project for the secondary objective.
Terahertz Metamaterials for Tumour Marker Concentration Identification
1 other identifier
observational
90
1 country
1
Brief Summary
The research the investigators plan to undertake involves the use of a metamaterial at terahertz frequencies. Serum samples will be tested using the metamaterial to determine if this method can be used to measure the concentration of tumour markers present in the sample. Patients who have been tested for CEA, LDH, CA-125, CA 19-9, CA 15-3, total-hCG and AFP will be used for both the positive and negative samples.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started May 2021
Longer than P75 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
October 8, 2019
CompletedFirst Posted
Study publicly available on registry
October 14, 2019
CompletedStudy Start
First participant enrolled
May 17, 2021
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
October 1, 2025
CompletedNovember 1, 2023
October 1, 2023
1.4 years
October 8, 2019
October 30, 2023
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Evidence of detection for any marker
Any correlation showing a difference between samples with marker concentrations above and below the standard threshold values used for tests within the NHS.
18 months
Secondary Outcomes (1)
Quantifying the quality of detection per marker
18 months
Interventions
A diagnostic test used to identify specific tumour markers will be carried out on serum samples using terahertz metamaterials.
Eligibility Criteria
County Durham and Darlington NHS Foundation Trust
You may qualify if:
- Any patient recommended by their health professional to be tested for any of the tumour markers being studied at County Durham and Darlington NHS Foundation Trust for any reason.
You may not qualify if:
- Patients with known bloodborne pathogens.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Department of Engineering Durham University
Durham, DH1 3LE, United Kingdom
Biospecimen
Surplus serum samples remaining after hospital tests.
MeSH Terms
Conditions
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
October 8, 2019
First Posted
October 14, 2019
Study Start
May 17, 2021
Primary Completion
October 1, 2022
Study Completion
October 1, 2025
Last Updated
November 1, 2023
Record last verified: 2023-10
Data Sharing
- IPD Sharing
- Will not share
Outcomes will be shared.